Active Filter(s):
Details:
Through the acquisition, Lucy adds Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CNS-related conditions.
Lead Product(s): Psilocybine,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: SANA-013
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Lucy Scientific Discovery
Deal Size: $0.5 million Upfront Cash: $0.4 million
Deal Type: Acquisition July 05, 2023
Details:
Through the acquisition, Lucy will add Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013 to its existing business of psychedelics manufacturing. SANA-013 is being developed for the treatment of several mental health/CNS-related conditions.
Lead Product(s): Psilocybine,Cannabidiol
Therapeutic Area: Psychiatry/Psychology Product Name: SANA-013
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Lucy Scientific Discovery
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 21, 2023
Details:
Results of the study showed that administration of imipramine given three weeks following a psilocybin loading dose provided an additional 39% further improvement in depressive behaviors from that of psilocybin loading dose alone.
Lead Product(s): Psilocybine,Imipramine
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
The Company received positive written responses from the FDA, outlining the requirements to open the IND and commence with clinical studies for SANA-013,for the treatment of Traumatic Brain Injury (TBI) related major depressive disorder.
Lead Product(s): Psilocybine,Cannabidiol
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: SANA-013
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2022